Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
Melissa M. Berrien-Elliott, Todd A. Fehniger(Washington University in St. Louis), Sweta Desai(Washington University in St. Louis), Carly C. Neal(Washington University in St. Louis), Amanda F. Cashen(Washington University in St. Louis), Sridhar Nonavinkere Srivatsan(Washington University in St. Louis), Iskra Pusic(Washington University in St. Louis), Michelle Becker‐Hapak(Washington University in St. Louis), Julia A. Wagner(Washington University in St. Louis), Timothy Schappe(Washington University in St. Louis), Rizwan Romee(Harvard University), John F. DiPersio(Washington University in St. Louis), Jennifer A. Foltz(The University of Texas MD Anderson Cancer Center), Matthew Cooper(Washington University in St. Louis), Natália Jaeger(Washington University in St. Louis), Camille N. Abboud(Washington University in St. Louis), Ethan McClain(Washington University in St. Louis), Mark P. Foster(Washington University in St. Louis), Celia C. Cubitt(Washington University in St. Louis), Keith Stockerl‐Goldstein(City Of Hope National Medical Center), Mark A. Schroeder(MACOM (United States)), Geoffrey L. Uy(Memorial Sloan Kettering Cancer Center), Peter Westervelt(MACOM (United States)), Pamela Wong(Washington University in St. Louis), Meagan A. Jacoby(MACOM (United States)), Feng Gao(Washington University in St. Louis)
Cited by 146
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Granzyme B and Perforin Are Important for Regulatory T Cell-Mediated Suppression of Tumor Clearance
|Immunity|2007|988
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
|Science Translational Medicine|2016|916
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782